the analysis of survival rate depending on scheme PVT
At patients from both groups differences in survival rate SVO depending on scheme PVT (the Appendix 1, tab have been taped. 8 and 9).
At patients HGV receiving rekombinantnyj INF a-2b 3 times in ned + Lamivudin (scheme PVT 1), the cumulative share of survival SVO at the moment of time at a stage of 12 and 24 months has made 0,600±0,155 and 0,200±0,126 accordingly, further in group has been taped active replikatsija a virus.
At the patients receiving rekombinantnyj INF a-2b daily + Lamivudin (scheme PVT 2), a cumulative share of survival SVO at the moment of time at stages of 12 and 36 months has made 0,636±0,145, 0,188±0,098 accordingly, further all patients had active replikatsiju a virus (fig. 25).
Fig. 25. Function of attainig the age SVO at patients HGV depending on scheme PVT
Average time of attainig the age SVO for patients with at PVT (1) has made 8,000±2,567, for patients with PVT (2) - 7,579±2,464 (tab. 125).
Table 125
Averages and medians of time of attainig the age SVO at patients HGV in dependence
From scheme PVT
HG | The scheme PVT | Average! 1 | Median | ||||||
Estimation | The item an error | 95 % the confidential Interval | Estimation | The item Error | 95 % a confidential interval | ||||
The bottom Border | The top Border | The bottom border | The top border | ||||||
IN | 1 | 8,000 | 2,567 | 2,969 | 13,031 | 0,000 | 8,000 | ||
2 | 7,579 | 2,464 | 2,749 | 12,409 | 0,000 | 7,579 |
At patients HGS receiving rekombinantnyj INF a-2b 3 times in ned + (scheme PVT 1), a cumulative share of survival SVO at the moment of time at a stage
12 and 24 months has made 0,300±0,145 and 0,200±0,126 accordingly, further at a stage 48 mes indicator CENSORED is noted. At the patients receiving rekombinantnyj pegelirovannyj INF a-2b + ribavirin (the scheme
PVT 2), at all finished observation at a stage 48 mes indicator CENSORED ^^^) is noted.
Fig. 26. Function of attainig the age SVO at patients HGS depending on the scheme
PVT
Average time of attainig the age SVO for patients with at PVT (1) has made 24,358±2,254, for patients with PVT (2) - 6,000±2,462 (tab. 126).
Table 126
Averages and medians of time of attainig the age SVO at patients HGS depending on scheme PVT
HG | The scheme PVT | Sredneea | Median | ||||||
Estimation | The item Error | 95 % a confidential interval | Estimation | The item an error | 95 % a confidential interval | ||||
The bottom Border | The top Border | The bottom border | The top border | ||||||
WITH | 1 | 24,358 | 2,254 | 0,000 | 48,000 | 0,000 | 24,358 | ||
2 | 6,000 | 2,462 | 6,000 | 24,000 | 0,000 | 6,000 |
Thus, as a whole survival rate SVO at HGS above, than at HGV. Some factors influence this indicator at patients with HGV. prediktorom the female is positive. At girls in 5 times more time of conservation SVO (proof remission). At initially low virus load at the patients who have reached SVO, stable remission remained more longly more, than in 2 times. The nationality of the patient, as well as frequency rate of introduction INF and - 2b short action did not influence duration of conservation SVO.
At girls with HGS also proof remission was observed almost in 2 times more longly, than at boys. At patients with HGS the high virus load was positive preditktorom conservations of stable remission. The choice of the combined therapy pegelirovannym INF a-2 and ribavirinom has allowed to keep proof remission to all patients who have finished observation.
Ñêà÷àòü îðèãèíàë èñòî÷íèêà